KLBF:IDXPT Kalbe Farma Tbk Analysis
Data as of 2026-07-25 - not real-time
IDR 720.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading below its 20‑day simple moving average, confirming a short‑term bearish bias, yet the MACD histogram has turned positive and the RSI sits in the mid‑range, suggesting limited downside and potential for a rebound. Volume is on the rise, providing liquidity support as the price hovers near a key support zone while the next resistance level remains well above current levels.
Fundamentally, the company trades at a price‑earnings multiple far below the industry average, delivering an attractive dividend yield and a payout ratio that appears sustainable given strong operating cash flow. A discounted cash‑flow model indicates a sizable upside, and the balance sheet shows ample cash relative to debt, reinforcing a resilient financial profile despite elevated 30‑day volatility and a historically large drawdown.
Fundamentally, the company trades at a price‑earnings multiple far below the industry average, delivering an attractive dividend yield and a payout ratio that appears sustainable given strong operating cash flow. A discounted cash‑flow model indicates a sizable upside, and the balance sheet shows ample cash relative to debt, reinforcing a resilient financial profile despite elevated 30‑day volatility and a historically large drawdown.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price below short‑term SMA indicating bearish pressure
- MACD histogram turning positive suggests momentum shift
- increasing volume provides support for near‑term stability
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- valuation gap with peers offers clear upside
- strong cash generation and sustainable dividend
- DCF fair‑value estimate well above current price
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- robust ROE and earnings growth underpin long‑term earnings potential
- defensive healthcare sector reduces cyclical exposure
- healthy balance sheet and low beta mitigate market volatility
Key Metrics & Analysis
Financial Health
Revenue Growth10.10%
Profit Margin9.99%
P/E Ratio9.0
ROE14.43%
ROA9.02%
Debt/Equity1.19
P/B Ratio1.3
Op. Cash FlowIDR3190.3B
Free Cash FlowIDR2396.1B
Industry P/E29.3
Technical Analysis
TrendBearish
RSI43.2
SupportIDR 700.00
ResistanceIDR 810.00
MA 20IDR 741.00
MA 50IDR 753.50
MA 200IDR 1,019.13
MACDBullish
VolumeIncreasing
Fear & Greed Index88.25
Valuation
Fair ValueIDR 1,127.60
Target PriceIDR 1,270.29
Upside/Downside76.43%
GradeUndervalued
TypeBlend
Dividend Yield2.78%
Risk Assessment
Beta0.26
Volatility45.24%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.